Ryz711

Preclinical

RRayzeBio, Inc.

Ryz711 is one of 10 therapeutic programs targeting Prostate Cancer (Adenocarcinoma). It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Prostate Cancer (adenocarcinoma)Not yet recruiting

Prostate Cancer (adenocarcinoma)Preclinical

Not yet recruiting

Competition

Competitive Landscape

9 competitors in Prostate Cancer (adenocarcinoma)

#DrugCompanyPhaseTrials

Xtandi

Astellas

Phase 3

1 2

Nubeqa

Bayer

Phase 3

1 3

Erleada

Johnson & Johnson

Phase 3

1 4

Zytiga

Johnson & Johnson

Phase 3

1 5

Taxotere

AAvyxa

Phase 3

2 6

Talzenna

Pfizer

Phase 2

1 7

Androgen Deprivation Therapy

Johnson & Johnson

Preclinical

1 8

Docetaxel /m²

AstraZeneca

Phase 1

1 9

Gallium Ga 68 Gozetotide

MMayo Clinic

Preclinical

1 10

Ryz711

RRayzeBio, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

PreclinicalNot yet recruiting

Prostate Cancer (adenocarcinoma)

NCT07862582

Clinical

Trials by Indication[1]

Prostate Cancer (Adenocarcinoma)1 trial

Phase 1 /2 Multicenter, Basket, Imaging Study Investigating the Safety and Diagnostic Performance of RYZ711 in Men With Prostate Cancer.

Not yet recruiting·RRayzeBio, Inc.·Preclinical·NCT07862582·116 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Ryz711. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Ryz711. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — RayzeBio, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: RRayzeBio, Inc.

Ryz711

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Prostate Cancer (Adenocarcinoma)1 trial

References

Drug Info

Quick Facts

Related News